Showing 1 - 10 of 136
In the past few years, several papers have been published in the international literature on the impact of the economic crisis on health and health care. However, there is limited knowledge on this topic regarding the Central and Eastern European (CEE) countries. The main aims of this study are...
Persistent link: https://www.econbiz.de/10011287993
In the past few years, several papers have been published in the international literature on the impact of the economic crisis on health and health care. However, there is limited knowledge on this topic regarding the Central and Eastern European (CEE) countries. The main aims of this study are...
Persistent link: https://www.econbiz.de/10011255327
Background Health systems are undertaking eforts to make health care more patient centered and value based. To achieve this goal, the use of patient-reported experience measures (PREMs) is increasing, especially across OECD countries. However, in Hungary, data on patients’ experiences are...
Persistent link: https://www.econbiz.de/10012582906
Background The objective of this paper is to explore unmet health care needs in Hungary in ambulatory care due to costs and difculties in travelling, and to analyze how unmet needs relate to socio-demographic characteristics. Methods The quantitative analysis is based on a national,...
Persistent link: https://www.econbiz.de/10012582907
Persistent link: https://www.econbiz.de/10012060929
Persistent link: https://www.econbiz.de/10012060932
Persistent link: https://www.econbiz.de/10008497312
Persistent link: https://www.econbiz.de/10010434928
OBJECTIVES: To compare the efficacy and safety of infliximab-biosimilar with other biological drugs for the treatment of active ankylosing spondylitis (AS). METHODS: Systematic literature review for randomized controlled trials (RCTs) with adalimumab, etanercept, golimumab, infliximab and...
Persistent link: https://www.econbiz.de/10010434939
OBJECTIVE: The aim of this meta-analysis was to compare the efficacy and safety of infliximab-biosimilar and other available biologicals for the treatment of rheumatoid arthritis (RA), namely abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab....
Persistent link: https://www.econbiz.de/10010434940